Recent Updates
Recently added Catalysts
NRSN Neutral Sentiment Score: 60/100

Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend an Annual

Key Takeaway: NeuroSense Therapeutics Ltd. has announced its Annual General Meeting of Shareholders to take place on June 27, 2024, at their offices in Herzliya, Israel. The agenda includes the approval of a bonus plan for CEO Alon Ben-Noon and the renewal of his employment agreement. Shareholders are encouraged to vote either online or by mail to ensure their shares are represented. Further details will be provided in the Proxy Statement.

Market Sentiment Analysis

Full Press Release Details

11 Hamenofim St., Building B, Herzliya 4672562,
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON JUNE 27, 2024
Dear NeuroSense Therapeutics Ltd. Shareholders:
We cordially invite you to
attend an Annual General Meeting of Shareholders (the "Meeting"), of NeuroSense Therapeutics Ltd. (the "Company"),
to be held at 11:00 a.m. (Israel time) on June 27, 2024 at our offices at 11 Hamenofim St., Building B, Herzliya 4672562, Israel.
The Meeting is being called
for the following purposes:
6. To approve a 2024 bonus plan for Mr. Alon Ben-Noon, Chief Executive Officer of the Company, based on the achievement of certain Company milestones.
7. To approve the renewal of Mr. Alon Ben-Noon's employment agreement with the Company.
The Company is currently unaware
of any other matters that may be raised at the Meeting. Should any other matters be properly raised at the Meeting, the persons designated
as proxies shall vote according to their own judgment on those matters. Our Board of Directors unanimously recommends that you vote in
favor of the above proposal, which will be described in the Proxy Statement to be provided separately.
Shareholders of record at
the close of business on May 24, 2024 are entitled to notice of and to vote at the Meeting.
Whether or not you plan to
attend the Meeting, it is important that your shares be represented and voted at the Meeting. Accordingly, after reading the Notice of
Annual General Meeting of Shareholders and the Proxy Statement to be provided separately, please (i) vote online or (ii) mark, date, sign
and mail the enclosed proxy or voting instruction form as promptly as possible in the enclosed stamped envelope. If voting by mail, the
proxy must be received by Broadridge Financial Solutions, Inc. at least 48 hours (or such shorter period as the Chairman of the Meeting
may determine) prior to the appointed time of the Meeting to be validly included in the tally of ordinary shares voted at the Meeting.
An earlier deadline may apply to receipt of your voting instruction form, if indicated therein. Detailed proxy voting instructions are
provided both in the Proxy Statement and on the enclosed proxy card and voting instruction form. In the alternative, shareholders who
hold their shares in street name may be able to utilize the control number appearing on their voting instruction form to submit their
voting instruction to their brokers, trustees or nominees by other means, if so indicated on their voting instruction form.
NeuroSense Therapeutics Ltd.

Frequently Asked Questions

When is the Annual General Meeting for NeuroSense Therapeutics?

The Annual General Meeting is scheduled for June 27, 2024, at 11:00 a.m. Israel time.

What is the purpose of the shareholder meeting?

The meeting aims to approve a 2024 bonus plan and the renewal of the CEO's employment agreement.

Who can vote at the Annual General Meeting?

Shareholders recorded as of May 24, 2024, can vote at the meeting.

How can shareholders vote if they can't attend?

Shareholders can vote online or by mailing a signed proxy form in the provided envelope.

What happens if I vote by mail?

If voting by mail, your proxy must reach Broadridge Financial Solutions 48 hours before the meeting.

Last updated: May 23, 2024